Leflunomide medac 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0038 
Minor change in labelling or package leaflet not 
31/10/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0037 
Minor change in labelling or package leaflet not 
07/03/2023 
04/05/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
N/0036 
Minor change in labelling or package leaflet not 
03/02/2023 
04/05/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0035 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/05/2022 
04/05/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PSUSA/1837/
Periodic Safety Update EU Single assessment - 
06/05/2021 
n/a 
PRAC Recommendation - maintenance 
202009 
leflunomide 
IAIN/0033 
B.III.1.a.3 - Submission of a new/updated or 
22/12/2020 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IB/0032 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/07/2020 
24/06/2021 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IA/0031 
B.III.1.a.2 - Submission of a new/updated or 
21/11/2019 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0030 
B.II.d.2.a - Change in test procedure for the finished 
14/06/2018 
n/a 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Minor changes to an approved test 
procedure 
PSUSA/1837/
Periodic Safety Update EU Single assessment - 
12/04/2018 
n/a 
PRAC Recommendation - maintenance 
201709 
leflunomide 
N/0029 
Minor change in labelling or package leaflet not 
30/01/2018 
21/06/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0027/G 
This was an application for a group of variations. 
18/07/2017 
21/06/2018 
SmPC, 
B.II.e.5.b - Change in pack size of the finished 
product - Deletion of a pack size(s) 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
PSUSA/1837/
Periodic Safety Update EU Single assessment - 
06/04/2017 
n/a 
PRAC Recommendation - maintenance 
201609 
leflunomide 
PSUSA/1837/
Periodic Safety Update EU Single assessment - 
14/04/2016 
n/a 
PRAC Recommendation - maintenance 
201509 
leflunomide 
IAIN/0025 
C.I.z - Changes (Safety/Efficacy) of Human and 
10/12/2015 
15/07/2016 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IA/0023 
C.I.z - Changes (Safety/Efficacy) of Human and 
31/07/2015 
15/07/2016 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IA/0022 
B.III.1.a.2 - Submission of a new/updated or 
08/07/2015 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
from an already approved manufacturer 
IA/0021/G 
This was an application for a group of variations. 
08/07/2015 
n/a 
B.II.e.4.a - Change in shape or dimensions of the 
container or closure (immediate packaging) - Non-
sterile medicinal products 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
PSUSA/1837/
Periodic Safety Update EU Single assessment - 
10/04/2015 
n/a 
PRAC Recommendation - maintenance 
201409 
leflunomide 
R/0019 
Renewal of the marketing authorisation. 
22/01/2015 
23/03/2015 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
including all variations introduced since the marketing 
and PL 
authorisation was granted, the CHMP considered that the 
benefit-risk balance of Leflunomide Medac in the approved 
indication remains favourable and therefore recommended 
the renewal of the marketing authorisation with unlimited 
validity. 
IB/0018 
C.I.2.a - Change in the SPC, Labelling or PL of a 
29/09/2014 
23/03/2015 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0017 
C.I.11.z - Introduction of, or change(s) to, the 
09/09/2014 
n/a 
obligations and conditions of a marketing 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
authorisation, including the RMP - Other variation 
IAIN/0016/G 
This was an application for a group of variations. 
10/06/2014 
23/03/2015 
SmPC, Annex 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
II, Labelling 
and PL 
PSUSA/1837/
Periodic Safety Update EU Single assessment - 
10/04/2014 
n/a 
PRAC Recommendation - maintenance 
201309 
leflunomide 
IB/0015 
C.I.z - Changes (Safety/Efficacy) of Human and 
23/03/2014 
23/03/2015 
SmPC and PL 
To add the patent protected indication ‘psoriatic arthritis’. 
Veterinary Medicinal Products - Other variation 
Subsequently the RMP was updated and adapted to the 
current format. In addition, the SmPC was brought in line 
with the latest QRD template. 
X/0012/G 
This was an application for a group of variations. 
30/05/2013 
25/07/2013 
SmPC, Annex 
Please refer to the assessment report Leflunomide medac-
II, Labelling 
H-1227-X-12-G-AR-Extension. 
and PL 
- To add a new strength. 
- To extend the shelf life of the finished product. 
- To replace the DDPS with a summary of PhV 
system. 
- To make some editorial changes. 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
Annex I_2.(c) Change or addition of a new 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
strength/potency 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
28/01/2013 
25/07/2013 
SmPC and PL 
Update of Sections 4.4 and 4.8 of the SmPC to add 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
cutaneous lupus erythematosus, pustular psoriasis or 
worsening psoriasis and warn physicians about these skin 
reactions in accordance with the reference product. The 
Package Leaflet was updated accordingly. 
N/0010 
"Update of the local representatives contact details 
17/09/2012 
29/10/2012 
PL 
for France and Italy." 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/06/2012 
29/10/2012 
SmPC, Annex 
Implementation of changes approved in reference product 
generic/hybrid/biosimilar products following 
II, Labelling 
– update of section 4.4 to add a warning for peripheral 
assessment of the same change for the reference 
and PL 
neuropathy and the frequency of this event has been 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
changed to ‘common’ in section 4.8 as requested by CHMP. 
The PIL has been updated accordingly. Further updates 
concern the implementation of the latest QRD template. In 
addition, the MAH updated the list of local representatives 
for Cyprus and Iceland. 
IB/0008 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/12/2011 
30/01/2012 
SmPC 
Update of section 4.4 of the SmPC regarding the risk of 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
leflunomide use in combination with biologicals following 
the CHMP assessment of the COLEBI study (FU2 038.1) as 
implemented in the originator product Arava II-49. 
IB/0007 
C.I.2.a - Change in the SPC, Labelling or PL of a 
15/09/2011 
n/a 
SmPC and PL 
Update of sections 4.2 and 5.1 of the SmPC to reflect the 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
outcome  of the clinical study R01143 (LEADER) regarding 
the use of a loading dose, as requested by CHMP. The MAH 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
also took the opportunity to make minor linguistic 
corrections to align with the reference product and made 
changes to the contact details of the local representatives 
in the package leaflets. 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
30/08/2011 
n/a 
SmPC, Annex 
Implementation of changes approved in reference product - 
generic/hybrid/biosimilar products following 
II and PL 
update of section 4.4 to amend the warning for interstitial 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
lung disease (ILD) as requested by CHMP. The PIL was 
revised accordingly. In addition the description of the risk 
of teratogenicity in the PIL was strengthened. Further 
updates concern the Annex IIB and the implementation of 
the latest QRD template 
IA/0006 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
05/08/2011 
n/a 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
IA/0005 
C.I.9.i - Changes to an existing pharmacovigilance 
30/06/2011 
n/a 
system as described in the DDPS - Change(s) to a 
DDPS following the assessment of the same DDPS in 
relation to another medicinal product of the same 
MAH 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/06/2011 
n/a 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
II, Labelling 
and PL 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data are submitted by the MAH 
Page 8/8 
 
 
 
 
 
 
 
